News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders
MONTREAL , March 6, 2019 /PRNewswire/ -  Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) is pleased to announce that it has obtained an interim order from the Québec Superior Court in connection with the previously announced plan of arrangement pursuant to which a wholly-owned subsidiary of Ipsen
View HTML
Toggle Summary Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 Financial Results and Conference Call
MONTREAL , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the company will not report its fourth quarter and year end
View HTML
Toggle Summary Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 Acquisition to transform Ipsen’s Rare Disease portfolio by leveraging Clementia’s expertise and
View HTML
Toggle Summary Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference
MONTREAL , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that management will host a conference call in conjunction with
View HTML
Toggle Summary Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
MONTREAL , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted
View HTML
Toggle Summary Clementia Announces the Departure of Chief Commercial Officer
MONTREAL , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the departure of Eric Grinstead as the Company’s chief
View HTML
Toggle Summary Clementia to Present at the Evercore ISI HealthCONx Conference
MONTREAL , Nov. 21, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins , Ph.D., chief executive officer and
View HTML
Toggle Summary Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
Recent FDA Meeting Identifies Path Towards NDA Submission in the Second Half of 2019 Financing Raises $75 million to Support a Potential Commercial Launch MONTREAL , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Clementia Announces Pricing of Public Offering of Common Shares
MONTREAL , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the pricing of an underwritten public offering of 5,300,000
View HTML
Toggle Summary Clementia Announces Proposed Public Offering of Common Shares
MONTREAL , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it intends to offer and sell, subject to market conditions,
View HTML